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MiR-9 promotes the phenotypic switch of vascular smooth muscle cells by targeting KLF5
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Background/aim: Diabetic vascular smooth muscle cells (VSMCs) are characterized by increased proliferation and migration. Small
noncoding microRNAs (miRNAs) have been considered critical modulators of the VSMC phenotypic switch after an environmental
stimulus. However, microRNA in high glucose-induced proinflammation and its atherogenic effect is still ambiguous.
Materials and methods: The technique of qRT-PCR was used to examine the expression of miR-9 in VSMCs. The downstream signaling
protein relative to miR-9 regulation, Krüppel-like factor 5, and some marker genes of contractile VSMCs were analyzed by western
blotting and qRT-PCR. Luciferase reporter assay was used to detect the expression of KLF5, which is regulated by miR-9. To examine
the function of a miR-9 inhibitor in VSMC proliferation and migration, VSMC proliferation and migration assays were performed.
Results: Reduced transcriptional levels of miR-9 and expression of specific genes of contractile VSMCs were observed in the SMC cell
line C-12511 treated with high glucose and SMCs, which were isolated from db/db mice. Moreover, the activity of KLF5 3′-UTR was
dramatically reduced by a miR-9 mimic and increased by a miR-9 inhibitor. The proliferation and migration of SMCs were reduced by
the miR-9 mimic.
Conclusion: miR-9 inhibits the proliferation and migration of SMC by targeting KLF5 in db/db mice.
Key words: miR-9, smooth muscle cells, proliferation, migration, KLF5

1. Introduction
Cardiovascular disease, especially atherosclerosis that may
result in mortality, is the leading complication in patients
with diabetes mellitus (1). The common pathological
characteristics of coronary atherosclerosis and subsequent
fatal or nonfatal myocardial infarction result in the VSMCs
regaining their ability to proliferate and migrate. It is
widely accepted that the phenotypic conversion of VSMCs
(vascular smooth muscle cells) might be the critical cause
of atherosclerosis lesion formation and restenosis after
angioplasty or bypass (2,3). The physiological contractile
phenotype of VSMC can undergo a phenotypic change
to the synthetic phenotype in response to pathological
environmental stimuli, such as platelet-derived growth
factors, hyperglycemia, and balloon injury. The synthetic
VSMCs regained the abilities of migration and proliferation
but resulted in the loss of contractility and subsequent
vessel occlusion.
Previous studies have shown that the proliferation
and hyperglycemia-induced inflammatory responses are

higher in VSMCs from a diabetic model than in those from
a healthy control (4,5), suggestive of abnormal regulation
of differentiation processes in diabetic VSMCs. Some key
pathological factors associated with diabetes, including
high glucose (HG), advanced glycation end products,
growth factors, and oxidized lipids, would promote VSMC
dysfunction in diabetic (db/db) mice. Nevertheless, little
is known about the mechanism of abnormal VSMC
proliferation and differentiation in patients with diabetes.
Therefore, the potential ability of VSMCs to dedifferentiate
in response to environmental cues such as growth factors,
inflammatory cytokines, and high glucose-induced
culture conditions should be further elucidated to clarify
the pathogenic mechanism of vascular diseases relative to
diabetes (6).
KLF5, a member of the family of Kruppel-like factors,
belongs to a group of transcription factors containing
zinc finger domains, and serves as a transcriptional
activator or repressor, regulating a variety of physiological
processes, including differentiation, development, and
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proliferation (7,8). However, KLF5 is also modulated by a
variety of biological mechanisms, including microRNA,
and other transcriptional factors (9–11). Previous
studies have demonstrated that KLF5 might contribute
to VSMC dedifferentiation and synthetic phenotype
change in balloon-injured artery and platelet-derived
growth factor (PDGF)-stimulated VSMCs (9). The study
revealed the conceivable regulation mechanism of VSMC
dedifferentiation in pathological conditions relative to
atherosclerosis formation, including stimulation by growth
factors and vascular endothelial injury.
It has been revealed that by regulating expression
of several transcription factors in various pathological
conditions, microRNAs influence VSMC differentiation and
proliferation (4). The microRNAs regulate their target genes
by inducing translational repression or mRNA degradation.
It has been reported that miR-663 might promote neointima
formation and the VSMC phenotypic switch by targeting
JunB/myosin light chain 9 expression (12). It has also been
suggested that several other miRNAs, such as miR-26a and
miR-22, also acted upon VSMC differentiation in the given
pathological conditions (13,14). However, the regulation
of microRNA is quite complicated and distinct in different
pathological conditions. The expression of multiple genes
might be regulated by microRNAs via their binding to
mRNA targets; the specific mRNA is also regulated by a
variety of microRNAs based on the accessible sequence of
3′-UTR region. MiR-9 has also been proven to be related
to the protective effect in VSMCs after balloon injury via
degeneration of platelet-derived growth factor receptor
(PDGFR) (15). However, miR-9 promoted the proliferation
of pulmonary artery smooth muscle cells (PASMCs) after
hypoxia stimulation, which demonstrated that miR-9 has
different effects in distinct pathological conditions (16).
Therefore, a continuous in-depth study is essential to
understand this comprehensive regulation mechanism.
In the present study, the differential expression of miR-9
in VSMCs from db/db mice and db/+ controls was found,
in reference to the sequencing profiles of small RNAs in
VSMCs from db/db mice. This highly conserved miRNA
promotes microglial activation and inflammatory responses
by targeting MCPIP1 and mediating NF-κB signaling (17),
but its function in VSMCs and diabetes complications is
unknown. By bioinformatic analysis, we then recognized
that KLF5 is the target gene of miR-9; KLF5 downregulates
the expression of myocardin. The downstream molecule
myocardin might be responsible for the phenotypic
conversion of VSMCs, which influences the dysregulation of
miR-9 in promoting VSMC dedifferentiation.
2. Materials and methods
2.1. Cell Culture
Human aortic SMCs (C-12511, Promocell, Karlsruhe,
Germany) and HEK293 cells were cultured in Dulbecco’s

modified Eagle’s medium (DMEM) (provided by Gibco
Life Technologies, Gaithersburg, MD, USA), which
contained 100 units/mL of penicillin, 100 μg/mL of
streptomycin, and 10% FBS, and was low in glucose in a
humidified incubator at 37 °C with 5% CO2.
2.2. Separation and culture of VSMC in mice
The study was approved by our Institutional Animal
Ethics Committee. VSMCs were derived from the thoracic
aorta of male db/db mice aged 10–12 weeks (B6.BKS(D)Leprdb/Nju) and nondiabetic db/+ mice (age-matched)
provided by the National Resource Center of Model
Mice (NRCMM) and Model Animal Research Center
of Nanjing University. The protocol was performed as
described previously (18). After the mice were killed, the
thoracic aortas were harvested. The adipose tissues and
connective tissues of the aorta were removed, and the
aortas were then incubated with DMEM/F12 + 0.2% BSA
which contained 0.3 mg/mL elastase (provided by Sigma,
St. Louis, MO, USA) and 1 mg/mL collagenase B (provided
by Roche, Basel, Switzerland) at 37 °C for 8–10 min. It was
further digested at 37 °C for 1 h following the removal of
the adventitia. The tissues were then cut into pieces and
centrifuged at 200 g at room temperature for 5 min. After
washing, the VSMC pellets were plated in DMEM-F/12,
which was supplemented with 100 μg/mL of streptomycin,
100 units/mL of penicillin, and 20% FBS. The purity of
VSMCs reached over 80% based on morphology under
light microscope and immunofluorescent staining for
α-smooth muscle actin. VSMCs were then cultured in
DMEM/F12 medium, which was supplemented with
streptomycin, penicillin, and 10% FBS. VSMCs from
passages 4–6 were used for the following experiments.
2.3. Oligo transfection, overexpression, or knockdown of
KLF5 and miR-9 in cultured VSMCs
The expression of miR-9 was decreased by the miR-9
inhibitor and increased by a miR-9 mimic (Thermo Fisher
Scientific, Waltham, MA, USA). KLF5 and myocardin
knockdown was performed using their respective
siRNA (si-KLF5, 100 nM, Thermo Fisher Scientific) and
siRNA-MYOCD (80 nM, Thermo Fisher Scientific). An
adenovirus which expressed KLF5 (Ad-KLF5) was used
for the KLF5 upregulation assay. Cells were transfected
using LipofectamineTM RNAiMAX (for oligonucleotides)
or Lipofectamine® 2000 according to the manufacturer’s
protocol. Vehicle, oligo controls (Thermo Fisher Scientific),
siRNA control (Thermo Fisher Scientific), and adenovirus
control (Ad-GFP) were also used.
2.4. Construction of the adenovirus vector
The construction of adenoviruses encoding mouse- or
human-KLF5 (Ad-KLF5), mice- or human-myocardin
(Ad-MYO), and GFP (Ad-GFP) was authorized by
Invitrogen. When VSMCs derived from mice aortas
or C-12511 cells attained 80% confluence, the cells
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were infected by KLF5 adenovirus or control virus at a
concentration of 106/50 μL cultured medium for 24 h
(MOI = 200~300) and treated for 12 h. Cells were then
collected and lysed for subsequent assays.
2.5. RNA analysis by quantitative real-time PCR (qRTPCR)
Total RNA was extracted by miRNAeasy mini kits
(217004, Qiagen, Hilden Germany) in accordance with the
manufacturer-supplied protocols. Reverse transcription
and qPCR were employed to analyze gene expression and
miRNA transcription. Following the reverse transcription
reactions, qPCR for miRNAs was carried out using a
miScript SYBR Green PCR Kit (provided by Qiagen); the
mRNA expression was analyzed using SYBR green PCR
master mix (provided by Applied Biosystems, Foster
City, CA, USA). All qPCR reactions were performed in
double wells on 7300 or 7500 qPCR equipment (Applied
Biosystems) in 20 µL total reaction volume. The 2-∆∆ Ct
method was used to analyze qPCR data. The transcriptional
level was normalized to the expressions of U6 and β-actin
for mRNAs and miRNAs, respectively. Fold-changes with
respect to the values of the db/+ or control samples were
used to describe the results. The sequences of the primers
used are shown as following: Calponin F: 5′-ATC GTT
GTA CAA TGGT-3′, R: 5′-TAC CCC ATT TGG CCA
TTT AAA AAT CT-3′; SMA F: 5′-TAC CTC ATT GGT
TAC TCC AGGT-3′, R: 5′-CTT AGT TAC CTG TTT
AGA TTG CC-3′; SM-22α F: 5′-GCC GTT ACC GTT
GAT CCA GTT TT-3′, R: 5′-GTT TTC CTA GTC CTT
CCG AT-3′; KLF5 F: 5′-GTC TAG TTC AGT CAG TTC
AGT TGCA-3′, R: 5′-GTC CCC AGC CAC CGT AAA
AAA TGAC-3′; GAPDH F: 5′-TTT TGG GCT CGG TGA
TTA CGA CCC AAA-3′, R: 5′-TGA TGA TTA GTT CAT
ACC ACA TGAC-3′; Myocardin F: 5′-TGT CAT GCC
ATG GCC CCC ATA GTT GGG TA-3′, R: 5′-TGT ACC
ATC CAT TTT TTG TGT GAAA-3′.
2.6. Western blot analysis
Proteins from the VSMCs of animals and cell lines were
extracted using lysis buffer (Boshide, Wuhan, China). After
equal amounts of proteins were separated by SDS-PAGE,
they were transferred onto a PVDF membrane (Millipore,
Burlington, MA, USA). They were blocked with 5% milk
in TTBS for 2 h at 37 °C, and incubated overnight at 4 °C
with the following primary antibodies: anti-KLF5 (1:500,
ab2433, Abcam), anti-SMA (1:1000, ab6594, Abcam),
anticalponin (1:1000, ab32360, Abcam), anticalponin
(1:1000, ab46794, Abcam), antiSM22α (1:1000, ab14106,
Abcam), antimyocardin (1:1500, ab203614, Abcam), and
antiGAPDH (1:1000, sc-47778, Santa Cruz Biotechnology,
Dallas, TX, USA). The membranes were washed and
incubated with the secondary antibodies for 1 h at 25 °C.
The gray value of the protein bands was detected by ECL
Fuazon Fx (Vilber Lourmat).
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2.7. Luciferase assay
For reporter assays, 3′-UTRs sequences of mice KLF5
and human KLF5 were amplified using specific PCR and
cloned into psiCHECK vectors (provided by Promega,
Madison, WI, USA), which were then placed downstream
of the luciferase reporter gene, Firefly and Renilla, based
on the standard procedures. DNA sequencing was used for
the verification of the cloned inserts. Using nucleofection,
the vectors carrying a 3′-UTR fragment of KLF5 mRNA,
which contained the luciferase reporter gene and putative
miR-9 binding sequence, were transfected into HEK293
cells with either oligo controls, miR-9 mimic, or a miR9 mimic inhibitor. The psiCHECK vectors with wild type
and mutational 3’UTR fragment of KLF5 were transfected
into the 293HEK cells. Then the dual luciferase assays were
performed to identify the specific binding site of miR-9 to
3’UTR fragment of KLF5. Two days later, the HEK293
cells were subjected to lysis, and dual luciferase assay kits
(provided by Promega, Madison, WI, USA) were used
to examine Firefly luciferase and Renilla activity. Firefly
luciferase activity was used for normalization of the results,
and fold-change over the control samples was employed to
describe the results.
2.8. Proliferation and migration of VSMCs
Proliferation of VSMCs in vitro was determined with
a Vybrant MTT Cell Proliferation Assay Kit (provided
by Invitrogen, Carlsbad, CA, USA), according to the
protocols provided by the manufacturer. VSMC migration
assays were performed as described previously (19).
SMCs were incubated in serum-free medium for 2 days.
A linear wound was then gently made at the center of the
cell monolayer using a 200 μL tip; the monolayer was then
subjected to stimulation with high glucose and dynamic
observation for 24 h. An Olympus IX 71 microscope was
used to capture images. Furthermore, a colorimetric BrdU
Cell Proliferation Assay (Roche, Basel, Switzerland) was
used to measure cell proliferation ability. 1.0 × 104 C12511
or VSMCs were cultivated in a 96-well plate. After 24 h,
serum containing medium was removed and replaced
with DMEM/F12 growth medium with 1% FBS. Cells were
then stimulated with 20 ng/mL PDGF-BB for 18 h. BrdU
labeling, cell fixation, BrdU antibody conjugation, and
color development were performed. Signal detection was
performed on a SpectraMax (Roche) ELISA plate reader.
2.9. Statistical analysis
SPSS 20.0 software was employed for statistical analysis.
The mean ± standard deviation (SD) of 3 independent
experiments was used to describe the data. The difference
between the 2 groups was analyzed using an unpaired
t-test. Comparisons of more than 2 groups were performed
with one-way analysis of variance (ANOVA). P values <
0.05 were considered statistically significant.
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3. Results
3.1. Expression of miR-9 and KLF5 in VSMCs from db/
db mice and high glucose-induced C-12511 cells
We identified the downregulation of miR-9 in diabetic
VSMCs by reference to the profile of diabetes-induced
miRNA (17); based on a bioinformatic analysis (microRNA
online predictive website microRNA.org), we presumed
that KLF5 could be the target gene of miR-9 (mirSVR =
–1.1778, PhastCons score = 0.5217) (Figure 1A). A previous
study demonstrated that miR-9 played an important role
in modulating neurogenesis and axonal extension, as well
as microglial inflammatory responses (17,20), but its role
in the regulation of VSMC phenotypic conversion after
high glucose stimulation was still unknown. To determine
the dose–response relationship between KLF5 expression
and glucose concentration, we performed an experiment
in which C-12511 cells were treated with various
concentrations of glucose (range: 5–25 mM) for 12 h; the
total RNA and protein was extracted from these cells. The
transcription levels of miR-9 in the VSMCs isolated from
db/db and db/+ mice were measured by qPCR. We found
a significantly reduced expression of miR-9 in db/db mice
compared to db/+ mice (supplementary Figure 1). The
VSMCs isolated from the db/+ control mice can also be
used to extract the total RNA and protein for performing
qPCR and Western blotting. As shown in Figures 1B
and 1C, when compared with the control animals and
cell group cultivated with low glucose, the expression of
miR-9 notably decreased in both the VSMCs from control
animals and the C-12511 cells treated with a concentration
of glucose over 20 mM. The upregulation of KLF5 was also
observed in C-12511 cells in a dose-dependent manner
(Figure 1D); KLF5 expression was significantly increased
in VSMCs from db/db mice, when compared to those of
the control animals (Figure 1E).
3.2. MiR-9 regulated the expression of KLF5 in VSMCs
KLF5 is a suppressive transcriptional factor functioning
through the interaction with the carboxy-terminal–
binding protein; it promotes dedifferentiation and
phenotypic conversion to synthetic VSMCs after induction
by PDGF and TNF-α (9,10). To investigate the role of
reduced miR-9 in vitro after high glucose stimulationmediated KLF5 upregulation, VSMCs were transfected
with a miR-9 mimic inhibitor or control before highglucose stimulation. We examined the remaining levels
of miR-9 after treatment with miR-9 inhibitors, and then
we measured the enhanced levels after induction of miR9 mimics (supplementary Figure 1). As expected, miR9 inhibitors further promoted the expression of KLF5
in C-12511 cells after high glucose stimulation, and in
VSMCs from db/db mice by RT-PCR (Figures 2A and
2B). It was also revealed that KLF5 protein expression was
markedly increased in miR-9 inhibitor-treated VSMCs

after high glucose stimulation in the immunoblot assays
(Figures 2C and 2D). To explore whether miR-9 could
bind to the 3′-UTR region of KLF5 mRNA and directly
inhibit its expression, the luciferase assay was carried out
in the HEK293 cells, in which the 3′-UTR fragment of
KLF5 mRNA was used to construct the psiCHECK vector.
As expected, only the miR-9 mimic inhibited luciferase
activity. The miR-9 inhibitor was cotransfected into the
HEK293 cells with the plasmid containing the 3′-UTR
region of KLF mRNA, increasing the luciferase activity
compared to the control inhibitor oligonucleotide (Figures
2E–2F). It was revealed that miR-9 can directly bind to
KLF5 and inhibit its expression, which further elucidated
the regulatory function of miR-9 in high glucose-mediated
KLF5 expression in VSMCs. With the luciferase assay, we
showed that miR-9 downregulated KLF5 expression in
C-12511 cells by high glucose stimulation and in VSMCs
from db/db mice by targeting the 3′-UTR region of KLF5
mRNA.
3.3. MiR-9 alleviates the phenotypic conversion of high
glucose-induced VSMCs by modulating the expression
of KLF5 and myocardin
To clear the availabilities of the reference gene in our
study, we selected another reference, PPIA, to assess the
expression stabilities in qPCR. No significant difference
was found regarding the expression of b-actin among
the groups treated with different oligonucleotides and
adenovirus vectors in C12511 cells (Supplementary Figure
2A). In addition, we found the expression trend among
different groups of KLF5 was consistent when b-actin was
regarded as the housekeeping gene (Supplementary Figure
2B). A molecule present downstream of KLF5, myocardin,
is considered a key modulator for VSMC differentiation
marker genes (10). A previous study has demonstrated
that KLF5 negatively regulates myocardin (21). To verify
this in C-12511 cells after high glucose stimulation and
in VSMCs from diabetic model animals, we analyzed the
expression of myocardin by qPCR after transfecting the
cells with siRNA-KLF5. The expression of myocardin and
the marker gene of the contractile phenotype was found to
be significantly increased in C-12511 cells (Figure 3A). To
define the relationship between the miR-9 downregulation
and phenotypic conversion, we examined the expression
of contractile marker genes. As shown in Figure 3 and
supplementary Figure 2, the expression of marker genes
of the contractile phenotype such as SMA, SM22α, and
calponin was significantly higher in C-12511 cells (Figure
3B and supplementary Figure 3A) incubated with highglucose culture medium, and in VSMCs from db/db mice
(Figure 3C and supplementary Figure 3B) after transfection
with miR-9 mimic compared to those transfected with the
control oligonucleotide, which suggests that the increased
expression of myocardin and reduced expression of KLF5
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Figure 1. High glucose cultivation induces miR-9 downregulation and the increased expression of KLF5. A. The 3′-UTR region of
KLF5 contains the binding site for miR-9. The target binding site is indicated in red. B. The decreased transcription level of miR-9
after induction with high glucose concentrations (over 20 mM) in VSMCs isolated from diabetic model animals; this was detected by
performing qRT-PCR. C. The transcription level of mature miR-9 decreased after induction with high glucose concentrations (over 20
mM) in C-12511 cells; this was detected by performing qRT-PCR. D and E. Western blot and qRT-PCR for detection of KLF5 expression
in C-12511 cells and VSMCs from the diabetic model. The expression of KLF5 significantly increased in C-12511 cells treated with high
glucose in a dose-dependent manner (D), and in VSMCs from the diabetic model animals and control (E). The expression level was
calculated by the ratio of the KLF5 to GAPDH or β-actin. Data are presented as mean ± SD; *P < 0.05 and **P < 0.01 by Student’s t-test.
All experiments were replicated at least 3 times.
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Figure 2. miR-9 regulated the expression of KLF5, and the miR-9 mimic attenuated the expression of KLF5 in VSMCs. A and B.
Validation of miR-9 targets in VSMCs. VSMCs were transfected with miR-9 inhibitor and control oligo by nucleofection. 48 h after
transfection, the expression of KLF5 was analyzed with qRT-PCR. HG: high glucose, LG: low glucose. The results showed that the
expression of KLF5 was positively regulated by the miR-9 inhibitor in both C-12511 cells and VSMCs from db/db mice. C and D. The
representative figures of immunoblot analysis show the expression of KLF5 in C-12511 and VSMCs isolated from db/db mice under
different conditions. HG: high glucose, LG: low glucose, HG + I: high glucose + inhibitor, HG + con: high glucose + control oligos. E
and F. The influence of miR-9 mimics (E) or inhibitors (F) on luciferase activity after the vectors with mutated and wild type 3’ UTR
fragments of KLF5 were transfected into the HEK293 cells. Con + WT: control oligos + wild type 3’ UTR fragment, Con + Mut: control
oligos + mutational 3’ UTR fragment. The results shown are representatives of 3 independent experiments. Data are presented as mean
± SD; *P < 0.05 vs. control oligo and **P < 0.01 by Student’s t-test. N = 5.

due to the induction of the miR-9 mimic might contribute
to the alleviation of phenotypic change. Furthermore,
the expression of some marker genes of the contractile

phenotype was lower after cotransfection with the miR-9
mimic and siRNA-MYOCD than with the miR-9 mimic
and siRNA control (Figure 3D). On the other hand,
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Figure 3. MiR-9 regulated the phenotypic conversion of high-glucose–induced VSMCs. A. 18 h after the C-12511 cells were treated with
high-glucose medium and transfected with siRNA-KLF5 or control, the expression of contractile marker genes was detected by qRTPCR. B and C. 24 h after VSMCs from the db/db mice and C-12511 cells were treated with high-glucose medium and transfected with
miR-9 mimic or control, the expression of myocardin and contractile marker genes was detected by Western blot. The representative
immunoblots of SMA, SM22α, and calponin are shown; the relative expressions were used to demonstrate the expression change of the
marker genes after the modulation of the miR mimic. D. The transcriptional level of contractile marker genes after the knockout of
myocardin by transfection with siRNA MYOCDE. The reduced expression after knockout of myocardin, as expected in both C-12511
cells and VSMCs from db/db mice. No significant difference in SM22α expression was observed in C-12511 cells. E. The transcriptional
level of contractile marker genes after overexpression of myocardin by transfection with AD-MYO. The expression of these genes
increased after transfection with AD-MYO, independent of the induction of miR-9 mimic. Data are presented as mean ± SD; *P < 0.05
vs. control oligo and **P < 0.01 by Student’s t-test. The results shown are representative of 3 independent experiments.
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the increased expression of these marker genes was
independent of the induction of the miR-9 mimic after
transfection with Ad-MYOCD (Figure 3E). The results
elucidated that miR-9 abrogated the dedifferentiation and
phenotypic conversion to synthetic VSMCs by suppressing
KLF5 inhibition and the expression of myocardin.
3.4. MiR-9 mimic and downregulation of KLF attenuated the migration and proliferation of VSMCs induced
by high glucose
The function of miR-9 in the proliferation and migration of
VSMCs was investigated. The cell proliferation of C-12511
cells and VSMCs were stimulated by high glucose (Figure
4A). In addition, the results of the Brdu cell proliferation
assay are presented in Figure 4B, which show that the miR9 eliminates proliferation of VSMCs when compared with
control oligonucleotide. Migration ability was evaluated by
the wound healing assays and the results indicated that the
migration of VSMC induced by high glucose was reversed
by the miR-9 mimic (Figures 4C and 4D). The migration
distance at different time points is presented in Figure 4E.
More importantly, Ad-KLF5 and siRNA-KLF5 contributed
to a difference in the proliferative and migration ability of
VSMCs by modulating the expression of KLF5 after high
glucose exposure. The application of ADV-KLF5 promoted
proliferation and migration, but siRNA-KLF5 had the
opposite effect on biological behavior, which demonstrates
that the downregulation of KLF5 via siRNA or miR-9 has
a negative influence on dedifferentiation and phenotypic
conversion.
4. Discussion
The phenotypic conversion from the physiological
contractile type to the synthetic type after various kinds
of extracellular stimuli and pathological conditions
is observed in many vascular diseases, especially
atherosclerosis, restenosis, and vascular aging (22). The
terminal differentiated VMSCs are characterized by
vascular smooth muscle contraction induced by AngII
(23). In some conditions stimulated by pathological
factors, such as inflammatory cytokines, and some growth
factors, the differentiated VSMCs change to the synthetic
type, with the decreased expression of some marker genes
and the recovery of the proliferative and migration abilities
(22,24). The dedifferentiated processes are regulated by a
complicated mechanism involving transcriptional factors
and noncoding small RNA. The synthetic VSMCs cannot
regain the ability to proliferate but can secrete extracellular
matrix and vasoactive substances, which results in intimal
hyperplasia and vascular stenosis. In atherosclerotic
lesions, the synthetics migrate to the intima and media
layer regions and ingest the excessive liquid, which
forms the foam cells (2,3). Therefore, an investigation of
the regulation mechanism of the phenotypic changes of

VSMCs is crucial for understanding the role of VSMC
dysfunction in vascular hyperplasia lesions, and to identify
the potential molecular target which could reverse the
dedifferentiation process.
In a previous study, PDGF, which is commonly known as
an important growth factor that results in VSMC phenotypic
conversion, promoted vascular intima hyperplasia and
VSMC proliferation after vascular endothelium damage.
Yunhui Cheng et al. have demonstrated that miR-145
decreased after PDGF stimulation; it modulated the VSMC
phenotype in cultured cells by upregulating KLF5 (9). It
has been proven that microRNA-663 plays a crucial role in
controlling human aortic smooth muscle cell proliferation
and neointima information after PDGF-BB induction by
targeting the degradation of JunB and Myl9 (12). These
facts demonstrate that the downregulation of microRNA
after pathological stimuli can control phenotypic changes
by targeting genes which influence the migration and
proliferation of VSMCs. Additionally, some transcriptional
factors are also involved in the dedifferentiation and
phenotype conversion.
Numerous studies have identified the role of
microRNA in various conditions. However, the regulation
of VSMC phenotypic conversion in diabetic conditions
is still ambiguous. Liang et al. have revealed the essential
role of Pin1 in type 2 diabetes via STAT3 signaling and
mitochondria-dependent pathways in restenosis (25). They
found that Pin1 enhanced the migration of VSMCs and
stimulated neointima hyperplasia after vascular injury by
boosting VSMC proliferation. The study provided evidence
that the modulation of the VSMC phenotype in diabetic
conditions might be an important factor contributing to
susceptibility to vascular diseases in patients with diabetes.
According to a previous study, a diabetic condition indeed
results in the different profile of microRNA, of which the
most abundant expression is miR-504, in db/db VSMCs.
It was reported that miR-504 and the gene Fgf13 in db/
db VSMCs were upregulated when compared to those
in db/+VSMCs, which promoted VSMC dysfunction by
regulating inflammatory responses and growth factor
signaling related to diabetic vascular complications. The
target genes of miR-504 are Grb10 and Egr2, and the
expression of inflammatory genes in VSMCs is promoted
by the inhibition of Erg2, which also promotes proliferation
and migration of VSMCs (22). Ham et al. (15) found that
miR-9 was targeted to degenerate platelet-derived growth
factor receptors (PDGFR) and protected the VSMCs from
balloon injury. But whether miR-9 inhibited proliferation
and migration of VSMCs is still unknown.
In the present study, we identified another microRNA,
miR-9, which decreased in VSMCs from db/db mice,
with reference to the transcriptional profile of microRNA
induced by diabetes from the previous study. The
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Figure 4. Effects of miR-9 and KLF5 on proliferation and migration in vascular smooth muscle cells (VSMCs). A and B. Cell proliferation
was assessed by the MTT and Brdu cell proliferation assays. Experiments were performed in both C-12511 cells after cultivation in
high glucose and VSMCs from db/db mice. C. VSMC migration was determined by a standard wound healing assay. D and E. The
quantitative statistical analysis of migration distance in different groups after 24 h and migration distance at different time points (6 h,
12 h, and 24 h). HG: high glucose, mimic: miR-9 mimic, siRNA: KLF5-siRNA, ADV: adenovirus vector coding KLF5 gene. Data are
presented as mean ± SD; *P < 0.05 vs. control oligo and **P < 0.01 by Student’s t-test. All of the experiments were replicated 3 times.
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interaction of miR-9 with the target gene was examined
using bioinformatic analysis. We found that KLF5, a key
molecular switch controlling the phenotypic change by
regulating marker genes such as SMA, calponin, and
SM22α, is the potential downstream target gene of miR-9.
We then confirmed the miR-9 transcriptional levels both
in vivo and in vitro, and detected the expression of putative
target genes in VSMCs from db/db mice and C-12511 cells
cultivated under high-glucose conditions. As expected,
the downregulation of miR-9 and the increased expression
of KLF5 were observed. According to a previous study,
the increased expression of KLF5 would attenuate the
expression of marker genes, such as SMA, calponin, and
SM22α, and promote the dedifferentiation of VSMCs. The
direct effect of miR-9 on KLF5 expression was analyzed
using the luciferase reporter assay. After confirmation
of its interaction with KLF5, we hoped to understand
whether the miR-9 inhibitor could reverse the phenotypic
change characteristic of reduced expression of marker
genes and the ability of VSMCs to migrate and proliferate.
The results showed that the inhibitor significantly
reversed the expression of marker genes. In the phenotype
investigation, our study provided preliminary data about
the proliferation and migration related phenotype, which
suggested that the miR-9 mimic partially inhibited the
growth and mobility of the VSMCs in environments
of high glucose stimulation. Unfortunately, we did not
perform the flow cytometry assay to evaluate the cell
proliferation and we only observed the increased uptake of
Brdu according to the Brdu staining. Therefore, we could
not completely verify the decreased proliferative activity.
The evaluation of migration abilities should also be further
assessed with more experiments, such as transwell assay,
to demonstrate the conclusion more precisely. To further
explore the downstream mechanism, we explored some

functional experiments and we concluded that myocardin
is another key molecule in controlling the phenotypic
conversion due to the negative influence of KLF5 and
its ability to promote differentiation from the bone
marrow stem cells to VSMCs. Moreover, a previous study
relative to myocardin/tmem16a signaling suggested that
myocardin promoted TMEM16A expression by binding to
SRF and activating the promoter of TMEM16A in human
aortic smooth muscle cells (HASMCs), which inhibited
angiotensin II-induced proliferation in smooth muscle cells
(26). Furthermore, the reduced expression of myocardin,
which is negatively regulated by the overexpression of
STAT3 after treatment with VEGF, would suppress the
myocardin-induced upregulation of VSMC contractile
phenotype-specific genes (27). These studies consistently
showed myocardin to be a negative regulator for growth
and phenotypic conversion. Therefore, we inferred that
myocardin plays a role in the inhibition of growth induced
by some pathological extracellular stimuli and contractile
VSMC differentiation. This notion was then identified
by the overexpression and knockout of myocardin via
transfection with Ad-myocardin or siRNA-MYOCD. It
was found that the positive effect of the miR-9 inhibitor
on VSMC differentiation was dependent on the presence
of the appropriate expression of myocardin, because the
regulation of miR-9 would be absent if the expression of
myocardin was silenced by siRNA-MYOCD.
In summary, our results demonstrate a novel regulation
mechanism involved in the phenotypic conversion
from contractile to synthetic VSMCs after high-glucose
stimulus or under diabetic conditions. We discovered a
potential target that could be considered a new application
in the reversion of dedifferentiation in diabetic VSMCs by
understanding the role of the miR-9/KLF5/myocardin axis
in the regulation of phenotypic conversion.
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Supplementary Figure 1. The decreased transcription levels of miR-9 in C-12511 and diabetic VSMCs treated with miR-9 mimic.
A. The decreased remaining transcription levels of miR-9 in C-12511 cells treated with miR-mimics and inhibitors. B. The decreased
remaining transcription levels of miR-9 in VSMCs cells treated with miR-mimics and inhibitors. Data are represented as mean ± SD.
The experiments were replicated 3 times. **P < 0.01, *P < 0.05.

Supplementary Figure 2. The expression stabilities of β-actin and change of KLF5 expression under different conditions. A. The similar
transcription levels of β-actin in C-12511 cells after treatment with miR-9 mimic, miR-inhibitors, ADV-KLF5, and siRNA-KLF5. The
PPIA served as reference gene. B. The expression trend of KLF5 among different groups on the condition that PPIA is the housekeeping
gene. Con: LG stimulation, HG: high-glucose stimulation, HG + M: HG + miR-9 mimics, HG + I: HG + inhibitors, HG + ADV: HG +
adenovirus vector, HG + siRNA: HG + small interference RNA. Data are represented as mean ± SD. The experiments were replicated 3
times. **P < 0.01, *P < 0.05.
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Supplementary Figure 3. The expression of marker genes of the contractile phenotype after induction of miR-9 mimic measured by
the qRT-PCR. A. The expression marker genes of the contractile phenotype in C-12511 cells. B. The expression marker genes of the
contractile phenotype in VSMCs from db/db diabetic mice. Data are represented as mean ± SD. The experiments were replicated 3
times. **P < 0.01, *P < 0.05.
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